Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function.
体外研究
The therapeutic potential of targeting NMII to enhance CEC migration is investigated using bovine corneal endothelial cells (BCECs). Blebbistatin, a direct myosin motor inhibitor, promotes migration and directional persistence in CECs through decreasing actin retrograde flow and increasing lamellipodial protrusion persistence to accelerate wound healing in vitro.
体内研究
Blebbistatin (0.05 mL, 20 μM; intracameral injection; daily; for 6 days; New Zealand white rabbits) treatment promotes wound healing in rabbit corneal endothelial scraping model.
Animal Model:
New Zealand white rabbits (16-20 weeks; 3-3.5 kg)
Dosage:
0.05 mL; 20 μM
Administration:
Intracameral injection; daily; for 6 days
Result:
Resulted in significant improvement of corneal clarity and corneal edema resolution, implying the restoration of an intact corneal endothelial monolayer.
分子式
C18H16N2O2
分子量
292.33
CAS号
674289-55-5
运输条件
Room temperature in continental US; may vary elsewhere.